Century Therapeutics Reports Q3 2026 Loss of $23.5 Million, Cash of $174.1 Million
Century Therapeutics reported a Q3 2026 net loss of $23.5M, narrower than the $34.4M loss in Q3 2025. R&D expenses fell to $18.1M, and cash reserves totaled $174.1M. The company expects its cash runway to extend into Q1 2029. CNTY-813, a diabetes therapy, is on track for an IND submission in Q4 2026, with initial data expected in H2 2027. CNTY-308, a CAR-iT cell therapy, is set to enter clinical testing in 2026. Joseph Truitt joined the board of directors.
How this was made

The 30-second read
Why it matters
The earnings beat on loss reduction and cash increase may attract short‑term buying interest.
Market read
Primary earnings disclosure for a micro‑cap biotech, modest trading relevance.
What to watch
Upcoming IND filing for CNTY-813 and entry of CNTY-308 into clinical testing could drive future volatility.
Background
Century Therapeutics filed an 8‑K reporting its Q3 2026 results and pipeline updates.
Ticker impact
Quarterly earnings release showing Q3 2026 net loss of $23.5M and cash runway to Q1 2029.
likely modest upside as loss narrowed and cash position improved
Investors may view reduced loss and higher cash as a positive trend, supporting a short-term price gain.
Market effects
Biotech sector may see slight sentiment lift from improved cash runway.
US biotech investors could adjust positions modestly.
Limited to niche biotech investors.
Counterpoint
Loss narrowing may be priced in; risk of further dilution or unmet milestones could pressure the stock.
Key entities
- companyCentury Therapeutics
US‑listed biotech (ticker CNTY) reporting Q3 2026 results.


